PF-06465469

• Description :

  PF-06465469 is a covalent inhibitor of ITK with an IC50 of 2 nM. PF-06465469 also inhibits BTK. PF-06465469 inhibits cell migration in response to CXCL12. PF-06465469 decreases PD-1 and LAG-3 expression. PF-06465469 can be used to study leukemia and T-cell lymphoma[1][2].

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319, H335, H413

• Target :

  Btk; CXCR; Itk; LAG-3; PD-1/PD-L1

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Immunology/Inflammation; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/pf-06465469.html

• Purity :

  99.48

• Solubility :

  DMSO : 11 mg/mL (ultrasonic)

• Smiles :

  O=C(NC1=CC=C(C(C)C)C(C)=C1)C2=CC=CC(C3=NN([C@H]4CN(C(C=C)=O)CCC4)C5=NC=NC(N)=C53)=C2

• Molecular Formula :

  C30H33N7O2

• Molecular Weight :

  523.63

• Precautions :

  H315, H319, H335, H413

• References & Citations :

  [1]Mamand S, et al. Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma. Sci Rep. 2018 Sep 21;8 (1) :14216.|[2]Fu Z, et al. IL-2-inducible T cell kinase deficiency sustains chimeric antigen receptor T cell therapy against tumor cells. J Clin Invest. 2024 Nov 26;135 (4) :e178558.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1407966-77-1]